409 related articles for article (PubMed ID: 26756760)
21. Prognostic Significance of Circulating Tumor Cells with Mesenchymal Phenotypes in Patients with Gastric Cancer: A Prospective Study.
Ishiguro Y; Sakihama H; Yoshida T; Ichikawa N; Homma S; Fukai M; Kawamura H; Takahashi N; Taketomi A
Ann Surg Oncol; 2021 Feb; 28(2):1178-1186. PubMed ID: 32770296
[TBL] [Abstract][Full Text] [Related]
22. High Expression of BCAR1 by Circulating Tumor Cells and Tumor Tissues Is Predictive of a Poor Prognosis of Early-Stage Lung Adenocarcinoma Potentially Due to Regulation of Epithelial-Mesenchymal Transition.
Jiang S; Mao C; Jiang B; Tan Q; Deng B
Technol Cancer Res Treat; 2020; 19():1533033820983086. PubMed ID: 33334252
[TBL] [Abstract][Full Text] [Related]
23. Patterns of circulating tumor cells identified by CEP8, CK and CD45 in pancreatic cancer.
Zhang Y; Wang F; Ning N; Chen Q; Yang Z; Guo Y; Xu D; Zhang D; Zhan T; Cui W
Int J Cancer; 2015 Mar; 136(5):1228-33. PubMed ID: 25042121
[TBL] [Abstract][Full Text] [Related]
24. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.
Krebs MG; Hou JM; Sloane R; Lancashire L; Priest L; Nonaka D; Ward TH; Backen A; Clack G; Hughes A; Ranson M; Blackhall FH; Dive C
J Thorac Oncol; 2012 Feb; 7(2):306-15. PubMed ID: 22173704
[TBL] [Abstract][Full Text] [Related]
25. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.
Pailler E; Adam J; Barthélémy A; Oulhen M; Auger N; Valent A; Borget I; Planchard D; Taylor M; André F; Soria JC; Vielh P; Besse B; Farace F
J Clin Oncol; 2013 Jun; 31(18):2273-81. PubMed ID: 23669222
[TBL] [Abstract][Full Text] [Related]
26. A Delay in Adjuvant Therapy Is Associated With Worse Prognosis Only in Patients With Transitional Circulating Tumor Cells After Resection of Pancreatic Ductal Adenocarcinoma.
Javed AA; Floortje van Oosten A; Habib JR; Hasanain A; Kinny-Köster B; Gemenetzis G; Groot VP; Ding D; Cameron JL; Lafaro KJ; Burns WR; Burkhart RA; Yu J; He J; Wolfgang CL
Ann Surg; 2023 Jun; 277(6):866-872. PubMed ID: 36111839
[TBL] [Abstract][Full Text] [Related]
27. Cancer Stem Cells, Epithelial to Mesenchymal Markers, and Circulating Tumor Cells in Small Cell Lung Cancer.
Pore M; Meijer C; de Bock GH; Boersma-van Ek W; Terstappen LW; Groen HJ; Timens W; Kruyt FA; Hiltermann TJ
Clin Lung Cancer; 2016 Nov; 17(6):535-542. PubMed ID: 27363902
[TBL] [Abstract][Full Text] [Related]
28. Circulating Tumor Cells Identify Early Recurrence in Patients with Non-Small Cell Lung Cancer Undergoing Radical Resection.
Bayarri-Lara C; Ortega FG; Cueto Ladrón de Guevara A; Puche JL; Ruiz Zafra J; de Miguel-Pérez D; Ramos AS; Giraldo-Ospina CF; Navajas Gómez JA; Delgado-Rodriguez M; Lorente JA; Serrano MJ
PLoS One; 2016; 11(2):e0148659. PubMed ID: 26913536
[TBL] [Abstract][Full Text] [Related]
29. Analogous detection of circulating tumor cells using the AccuCyte
van der Toom EE; Groot VP; Glavaris SA; Gemenetzis G; Chalfin HJ; Wood LD; Wolfgang CL; de la Rosette JJMCH; de Reijke TM; Pienta KJ
Prostate; 2018 Mar; 78(4):300-307. PubMed ID: 29285777
[TBL] [Abstract][Full Text] [Related]
30. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
[TBL] [Abstract][Full Text] [Related]
31. Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer.
Chen J; Cao S; Situ B; Zhong J; Hu Y; Li S; Huang J; Xu J; Wu S; Lin J; Zhao Q; Cai Z; Zheng L; Wang Q
J Exp Clin Cancer Res; 2018 Jun; 37(1):127. PubMed ID: 29954422
[TBL] [Abstract][Full Text] [Related]
32. Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancer.
Ito M; Horimoto Y; Tokuda E; Murakami F; Uomori T; Himuro T; Nakai K; Orihata G; Iijima K; Saito M
Med Oncol; 2019 Sep; 36(10):89. PubMed ID: 31520329
[TBL] [Abstract][Full Text] [Related]
33. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
[TBL] [Abstract][Full Text] [Related]
34. Circulating Tumor Cells as a Biomarker in Pancreatic Ductal Adenocarcinoma.
Liu H; Sun B; Wang S; Liu C; Lu Y; Li D; Liu X
Cell Physiol Biochem; 2017; 42(1):373-382. PubMed ID: 28558380
[TBL] [Abstract][Full Text] [Related]
35. Mesenchymal and Phosphatase of Regenerating Liver-3 Status in Circulating Tumor Cells May Serve as a Crucial Prognostic Marker for Assessing Relapse or Metastasis in Postoperative Patients With Colorectal Cancer.
Su P; Lai W; Liu L; Zeng Y; Xu H; Lan Q; Chu Z; Chu Z
Clin Transl Gastroenterol; 2020 Dec; 11(12):e00265. PubMed ID: 33512811
[TBL] [Abstract][Full Text] [Related]
36. Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal.
Gradilone A; Raimondi C; Nicolazzo C; Petracca A; Gandini O; Vincenzi B; Naso G; Aglianò AM; Cortesi E; Gazzaniga P
J Cell Mol Med; 2011 May; 15(5):1066-70. PubMed ID: 21352474
[TBL] [Abstract][Full Text] [Related]
37. CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival.
Lee SH; Kim H; Hwang JH; Shin E; Lee HS; Hwang DW; Cho JY; Yoon YS; Han HS; Cha BH
Pancreas; 2014 Apr; 43(3):380-8. PubMed ID: 24622067
[TBL] [Abstract][Full Text] [Related]
38. The clinical significance of circulating tumor cells and T lymphocyte subtypes in pancreatic cancer patients.
Xing Y; Zhang X; Qin F; Yang J; Ai L; Wang Q; Zhai Y
Bioengineered; 2022 Feb; 13(2):2130-2138. PubMed ID: 35034581
[TBL] [Abstract][Full Text] [Related]
39. Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.
Messaritakis I; Nikolaou M; Koinis F; Politaki E; Koutsopoulos A; Lagoudaki E; Vetsika EK; Georgoulias V; Kotsakis A
Lung Cancer; 2019 Sep; 135():33-39. PubMed ID: 31447000
[TBL] [Abstract][Full Text] [Related]
40. Dynamic changes of different phenotypic and genetic circulating tumor cells as a biomarker for evaluating the prognosis of RCC.
Wang ZL; Zhang P; Li HC; Yang XJ; Zhang YP; Li ZL; Xue L; Xue YQ; Li HL; Chen Q; Chong T
Cancer Biol Ther; 2019; 20(4):505-512. PubMed ID: 30359544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
